Phil Febbo

Febbo is in his present position since 2018, responsible for Illumina's medical strategy to drive genomic testing into healthcare practice. Previously, he was CMO of Genomic Health and professor of medicine and urology at the University of California, San Francisco, where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer. He currently serves on the board of the American College of Medical Genetics and Genomics Foundation.